1177 Aktienübersicht Sino Biopharmaceutical Limited, eine Investment-Holdinggesellschaft, ist ein pharmazeutisches Forschungs- und Entwicklungskonglomerat in der Volksrepublik China. Mehr Details
Belohnungen Risikoanalyse Bei unseren Risikoprüfungen wurden keine Risiken für 1177 festgestellt.
Alle Risikoprüfungen anzeigen Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
Sino Biopharmaceutical Limited Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Sino Biopharmaceutical Historische Aktienkurse Aktueller Aktienkurs HK$2.98 52-Wochen-Hoch HK$4.25 52-Wochen-Tief HK$2.29 Beta 0.68 1 Monat Veränderung -10.51% 3 Monate Veränderung -21.37% 1 Jahr Veränderung -10.24% 3 Jahre Veränderung -50.08% 5 Jahre Veränderung -60.58% Veränderung seit IPO 22.06%
Aktuelle Nachrichten und Updates
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21 Weitere Updates anzeigen
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21
Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States Nov 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Oct 21
Key Executive recently sold HK$51m worth of stock Oct 07
First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023) Sep 28
Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO Sep 27
Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024 Sep 16
Upcoming dividend of HK$0.03 per share Sep 03
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma Aug 28
First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023) Aug 14 Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma Aug 01
Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024 Jul 31
Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule Jul 18
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Jul 16
Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet Jul 15
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection Jun 25
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)" Jun 19 Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director Jun 06
Upcoming dividend of HK$0.03 per share Jun 04
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma May 24
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China May 10
Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022) May 01
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules May 01
Executive Chairwoman of the Board recently bought HK$5.8m worth of stock Apr 21
Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024 Mar 29
Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022) Mar 29
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024 Mar 28
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" Mar 16
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet Mar 13
Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 02
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart Feb 28
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion. Feb 08
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) Jan 23
Now 21% undervalued Jan 15
Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain Dec 28
Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma Dec 22
Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722 Dec 12
Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038 Dec 05
An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million. Nov 10
Investor sentiment improves as stock rises 16% Oct 30
Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug Oct 17 An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 11
Upcoming dividend of HK$0.02 per share at 2.7% yield Sep 27
Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA Sep 26
First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022) Aug 26
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023 Aug 26
Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 03
Key Executive recently bought HK$34m worth of stock Jul 04
Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms Jul 01
Upcoming dividend of HK$0.06 per share at 3.0% yield Jun 13
Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine May 24
Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection) May 11
Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock Apr 06
Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021) Apr 01
Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation Feb 11
Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer Jan 14
Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203" Dec 10
Less than half of directors are independent Nov 16 Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
Upcoming dividend of HK$0.06 per share Aug 30
Upcoming dividend of HK$0.06 per share Aug 30
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022 Aug 24
First half 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 1H 2021) Aug 24
Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022 Aug 12 Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule Jun 28
Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial Jun 15
Upcoming dividend of HK$0.04 per share Jun 08
Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139" May 24
Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020) May 02 Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial Apr 21
Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication Apr 20
Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE Apr 09
Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China Apr 08
Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020) Apr 02 Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022
Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHND5071 Obtained Approval for Clinical Trial Mar 30
Sino Biopharmaceutical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022 Mar 03
Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing Jan 22
Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate Granted by National Medical Products Administration Jan 12
Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial Dec 22
Founder & Senior Vice Chairman recently bought HK$29m worth of stock Oct 08
VP & Executive Director recently bought HK$12m worth of stock Sep 22
Upcoming dividend of HK$0.02 per share Sep 06
Founder & Senior Vice Chairman recently bought HK$101m worth of stock Sep 02
Second quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.019 in 2Q 2020) Sep 02 Aktionärsrenditen 1177 HK Pharmaceuticals HK Markt 7D -3.6% -2.7% -1.7% 1Y -10.2% -8.1% 16.5%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 1177 wie die Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von -8.1 erzielte.
Rendite vs. Markt: 1177 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 16.5 erzielte.
Preisvolatilität Is 1177's price volatile compared to industry and market? 1177 volatility 1177 Average Weekly Movement 3.5% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 6.8% 10% most volatile stocks in HK Market 14.5% 10% least volatile stocks in HK Market 3.2%
Stabiler Aktienkurs: 1177 hatte in den letzten 3 Monaten im Vergleich zum Hong Kong -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 1177Die wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Sino Biopharmaceutical Limited, eine Investment-Holding, ist ein pharmazeutisches Konglomerat für Forschung und Entwicklung in der Volksrepublik China. Das Unternehmen ist in drei Segmenten tätig: Modernisierte chinesische Arzneimittel und chemische Arzneimittel, Investitionen und Sonstige. Das Unternehmen bietet Onkologie-Medikamente an, darunter Anlotinib-Hydrochlorid-Kapseln unter der Marke Focus V, Penpulimab-Injektion unter der Marke Annike, Efbemalenograstin alfa-Injektion unter der Marke Yilishu, Pomalidomid-Kapseln unter der Marke Anyue, Bevacizumab-Injektion unter der Marke Anbeisi, Rituximab-Injektion unter der Marke Delituo und Trastuzumab zur Injektion unter der Marke Saituo; Medikamente zur Behandlung von Lebererkrankungen, wie Magnesium-Isoglycyrrhizinat-Injektion unter der Marke Tianqing Ganmei und Entecavir-Dispersions-Tabletten unter der Marke Runzhong; und Medikamente zur Behandlung von Atemwegserkrankungen, wie Budesonid-Suspension zur Inhalation unter der Marke Tianqing suchang und Colistimethat-Natrium zur Injektion unter der Marke Tianyun.
Mehr anzeigen Sino Biopharmaceutical Limited's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Sino Biopharmaceutical im Vergleich zum Marktanteil des Unternehmens? 1177 grundlegende Statistiken Marktanteil HK$54.25b Gewinn(TTM ) HK$2.27b Umsatz(TTM ) HK$29.49b
23.9x Kurs-Gewinn-Verhältnis
1.8x Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 1177 Gewinn- und Verlustrechnung (TTM ) Einnahmen CN¥27.79b Kosten der Einnahmen CN¥5.23b Bruttogewinn CN¥22.56b Sonstige Ausgaben CN¥20.41b Umsatz CN¥2.14b
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) 0.12 Bruttomarge 81.16% Nettogewinnspanne 7.71% Schulden/Eigenkapital-Verhältnis 22.6%
Wie hat sich 1177 auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden
1.9% Aktuelle Dividendenrendite
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/01/09 11:03 Aktienkurs zum Tagesende 2025/01/09 00:00 Gewinne 2024/06/30 Jährliche Einnahmen 2023/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .
Analysten-Quellen Sino Biopharmaceutical Limited wird von 51 Analysten beobachtet. 23 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Justin Liu BNP Paribas Securities (Asia) Ling Zhang BNP Paribas Securities (Asia) Wai Chak Yuen BOCI Research Ltd.
48 weitere Analysten anzeigen 
